

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78978 A1

- (51) International Patent Classification⁷: C12N 15/81, 9/02
- (21) International Application Number: PCT/US00/16671
- (22) International Filing Date: 16 June 2000 (16.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/140,703 24 June 1999 (24.06.1999) US
- (71) Applicant (for all designated States except US): ZYMO-GENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (71) Applicants and
(72) Inventors: MILLER, Brady, G. [US/US]; 6061 Village Bend Drive #1816, Dallas, TX 75206 (US). SLOAN, James, S. [US/US]; 6423 Northeast 154th Street, Kenmore, WA 98028 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): RAYMOND, Christopher, K. [US/US]; 2626 N.E. 86th Street, Seattle, WA 98115 (US). VANAJA, Erica [US/US]; 2309 N. 64th, Seattle, WA 98103 (US).
- (74) Agent: PARKER, Gary, E.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- With international search report.
 - Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PICHIA METHANOLICA GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE 1 PROMOTER AND TERMINATOR



(57) Abstract: Transcription promoter and terminator sequences from the *Pichia methanolica* glyceraldehyde-3-phosphate dehydrogenase 1 gene (*GAP1* gene) are disclosed. The sequences are useful within DNA constructs for the production of proteins of interest in cultured *P. methanolica* cells. Within the expression vectors, a *GAP1* promoter and/or a *GAP1* terminator is operably linked to a DNA segment encoding the protein of interest.

WO 00/78978 A1

Description

5 *PICHA METHANOLICA* GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE 1 PROMOTER AND TERMINATOR

BACKGROUND OF THE INVENTION

10 Methylotrophic yeasts are those yeasts that are able to utilize methanol
as a sole source of carbon and energy. Species of yeasts that have the biochemical
pathways necessary for methanol utilization are classified in four genera, Hansenula,
Pichia, Candida, and Torulopsis. These genera are somewhat artificial, having been
based on cell morphology and growth characteristics, and do not reflect close genetic
relationships (Billon-Grand, Mycotaxon 35:201-204, 1989; Kurtzman, Mycologia
15 84:72-76, 1992). Furthermore, not all species within these genera are capable of
utilizing methanol as a source of carbon and energy. As a consequence of this
classification, there are great differences in physiology and metabolism between
individual species of a genus.

 Methylotrophic yeasts are attractive candidates for use in recombinant
20 protein production systems for several reasons. First, some methylotrophic yeasts have
been shown to grow rapidly to high biomass on minimal defined media. Second,
recombinant expression cassettes are genomically integrated and therefore mitotically
stable. Third, these yeasts are capable of secreting large amounts of recombinant
proteins. See, for example, Faber et al., Yeast 11:1331, 1995; Romanos et al., Yeast
25 8:423, 1992; Cregg et al., Bio/Technology 11:905, 1993; U.S. Patent No. 4,855,242;
U.S. Patent No. 4,857,467; U.S. Patent No. 4,879,231; and U.S. Patent No. 4,929,555;
and Raymond, U.S. Patents Nos. 5,716,808, 5,736,383, 5,854,039, and 5,888,768.

 Previously described expression systems for methylotrophic yeasts rely
largely on the use of methanol-inducible transcription promoters. The use of methanol-
30 induced promoters is, however, problematic as production is scaled up to commercial
levels. The overall volume of methanol used during the fermentation process can be as
much as 40% of the final fermentation volume, and at 1000-liter fermentation scale and
above the volumes of methanol required for induction necessitate complex and
potentially expensive considerations.

35 There remains a need in the art for additional materials and methods to
enable the use of methylotrophic yeasts for production of polypeptides of economic

importance, including industrial enzymes and pharmaceutical proteins. The present invention provides such materials and methods as well as other, related advantages.

SUMMARY OF THE INVENTION

5 Within one aspect, the present invention provides an isolated DNA molecule of up to 1500 nucleotides in length comprising nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.

 Within a second aspect of the invention there is provided a DNA construct comprising the following operably linked elements: a first DNA segment
10 comprising at least a portion of the sequence of SEQ ID NO:1 from nucleotide 733 to nucleotide 1732, wherein the portion is a functional transcription promoter; a second DNA segment encoding a protein of interest other than a *Pichia methanolica* glyceraldehyde-3-phosphate dehydrogenase; and a third DNA segment comprising a transcription terminator. Within one embodiment, the first DNA segment is from 900
15 to 1500 nucleotides in length. Within another embodiment, the first DNA segment is from 900 to 1000 nucleotides in length. Within a further embodiment, the first DNA segment comprises nucleotide 810 to nucleotide 1724 of SEQ ID NO:1. Within an additional embodiment, the first DNA segment is essentially free of DNA encoding a *P. methanolica* glyceraldehyde-3-phosphate dehydrogenase. The DNA construct may
20 further comprise a selectable marker, such as a *P. methanolica* gene, for example a *P. methanolica ADE2* gene. The DNA construct may be a closed, circular molecule or a linear molecule. Within other embodiments, the DNA construct further comprises a secretory signal sequence, such as a *Saccharomyces cerevisiae* alpha-factor pre-pro sequence, operably linked to the first and second DNA segments. Within additional
25 embodiments, the third DNA segment comprises a transcription terminator of a *P. methanolica AUG1* or *GAP1* gene.

 Within a third aspect of the invention there is provided a *P. methanolica* cell containing a DNA construct as disclosed above. Within one embodiment, the DNA construct is genomically integrated. Within a related embodiment, the DNA construct
30 is genomically integrated in multiple copies. Within a further embodiment, the *P. methanolica* cell is functionally deficient in vacuolar proteases proteinase A and proteinase B.

 Within a fourth aspect of the invention there is provided a method of producing a protein of interest comprising the steps of (a) culturing a *P. methanolica*
35 cell as disclosed above whereby the second DNA segment is expressed and the protein of interest is produced, and (b) recovering the protein of interest.

Within a fifth aspect of the invention there is provided a DNA construct comprising the following operably linked elements: a first DNA segment comprising a *P. methanolica* gene transcription promoter; a second DNA segment encoding a protein of interest other than a *P. methanolica* protein; and a third DNA segment comprising
5 nucleotides 2735 to 2795 of SEQ ID NO:1.

These and other aspects of the invention will become evident upon reference to the following detailed description of the invention and the attached drawings.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the vector pBM/GAP, comprising the *P. methanolica* *GAP1* promoter.

Fig. 2 illustrates the vector pTAP76.

15 DETAILED DESCRIPTION OF THE INVENTION

The term "allelic variant" is used herein to denote an alternative form of a gene. Allelic variation is known to exist in populations and arises through mutation.

A "DNA construct" is a DNA molecule, either single- or double-stranded, that has been modified through human intervention to contain segments of
20 DNA combined and juxtaposed in an arrangement not existing in nature.

A "DNA segment" is a portion of a larger DNA molecule having specified attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, that, when read from the 5' to the 3' direction, encodes the sequence of amino acids of the
25 specified polypeptide.

The term "functionally deficient" denotes the expression in a cell of less than 10% of an activity as compared to the level of that activity in a wild-type counterpart. Often the expression level will be less than 1% of the activity in the wild-type counterpart, frequently less than 0.01% as determined by appropriate assays. In
30 some instances it is desirable that the activity be essentially undetectable (i.e., not significantly above background). Functional deficiencies in genes can be generated by mutations in either coding or non-coding regions.

The term "gene" is used herein to denote a DNA segment encoding a polypeptide. Where the context allows, the term includes genomic DNA (with or
35 without intervening sequences), cDNA, and synthetic DNA. Genes may include non-coding sequences, including promoter elements.

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those
5 that are separated from their natural environment and include cDNA and genomic clones.

"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the
10 terminator.

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules.
15 Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When these terms are applied to double-stranded molecules they are used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those
20 skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired. Such unpaired ends will in general not exceed 20 nt in length.

A "polypeptide" is a polymer of amino acid residues joined by peptide
25 bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly,
30 but not always, found in the 5' non-coding regions of genes. Sequences within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. These promoter elements include RNA polymerase binding sites, TATA sequences, and transcription factor binding sites. Of particular interest within the present invention are Gcr1p binding sites, characterized by the
35 consensus sequences CTTCC or GGAAG, and Rap1p binding sites. See, in general, Watson et al., eds., Molecular Biology of the Gene, 4th ed., The Benjamin/Cummings Publishing Company, Inc., Menlo Park, CA, 1987.

A "pro sequence" is a DNA sequence that commonly occurs immediately 5' to the mature coding sequence of a gene encoding a secretory protein. The pro sequence encodes a pro peptide that serves as a cis-acting chaperone as the protein moves through the secretory pathway.

5 A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are commonly defined in terms of their amino acid backbone structures;
10 substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in
15 which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway. A secretory peptide and a pro peptide may be collectively referred to as a pre-pro peptide.

The present invention provides isolated DNA molecules comprising a *Pichia methanolica* glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
20 promoter. The invention also provides isolated DNA molecules comprising a *P. methanolica* GAPDH gene terminator. The promoter and terminator can be used within methods of producing proteins of interest, including proteins of pharmaceutical or industrial value.

The sequence of a DNA molecule comprising a *P. methanolica* glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene promoter, coding region,
25 and terminator is shown in SEQ ID NO:1. The gene has been designated *GAP1*. Those skilled in the art will recognize that SEQ ID NO:1 represents a single allele of the *P. methanolica* *GAP1* gene and that other functional alleles (allelic variants) are likely to exist, and that allelic variation may include nucleotide changes in the promoter region,
30 coding region, or terminator region.

Within SEQ ID NO:1, the GAPDH open reading frame begins with the methionine codon (ATG) at nucleotides 1733 - 1735. The transcription promoter is located upstream of the ATG. Gene expression experiments showed that a functional promoter was contained within the ca. 900 nucleotide 5'-flanking region of the *GAP1*
35 gene. Analysis of this promoter sequence revealed the presence of a number of sequences homologous to *Saccharomyces cerevisiae* promoter elements. These sequences include a consensus TATAAA box at nucleotides 1584 to 1591, a consensus

Rap1p binding site (Graham and Chambers, *Nuc. Acids Res.* 22:124-130, 1994) at nucleotides 1355 to 1367, and potential Gcr1p binding sites (Shore, *Trends Genet.* 10:408-412, 1994) at nucleotides 1225 to 1229, 1286 to 1290, 1295 to 1299, 1313 to 1317, 1351 to 1354, 1370 to 1374, 1389 to 1393, and 1457 to 1461. While not wishing
5 to be bound by theory, it is believed that these sequences may perform functions similar to those of their counterparts in the *S. cerevisiae TDH3* promoter (Bitter et al., *Mol. Gen. Genet.* 231:22-32, 1991), that is, they may bind the homologous transcription regulatory elements. Mutation of the region around the consensus Gcr1p binding site in the *P. methanolica GAPI* promoter has been found to destroy promoter activity.

10 Preferred portions of the sequence shown in SEQ ID NO:1 for use within the present invention as transcription promoters include segments comprising at least 900 contiguous nucleotides of the 5' non-coding region of SEQ ID NO:1, and preferably comprising nucleotide 810 to nucleotide 1724 of the sequence shown in SEQ ID NO:1. Those skilled in the art will recognize that longer portions of the 5' non-
15 coding region of the *P. methanolica GAPI* gene can also be used. Promoter sequences of the present invention can thus include the sequence of SEQ ID NO:1 through nucleotide 1732 in the 3' direction and can extend to or beyond nucleotide 232 in the 5' direction. For convenience and ease of manipulation, the promoter used within an expression DNA construct will generally not exceed 1.5 kb in length, and will often not
20 exceed 1.0 kb in length.

As disclosed in more detail in the examples that follow, the sequence of SEQ ID NO:1 from nucleotide 810 to 1724 provides a functional transcription promoter. However, additional nucleotides can be removed from either or both ends of this sequence and the resulting sequence tested for promoter function by joining it to a
25 sequence encoding a protein, preferably a protein for which a convenient assay is readily available.

Within the present invention it is preferred that the *GAPI* promoter be substantially free of *GAPI* gene coding sequence, which begins with nucleotide 1733 in SEQ ID NO:1. As used herein, the term "substantially free of *GAPI* gene coding
30 sequence" means that the promoter DNA includes not more than 15 nucleotides of the *GAPI* coding sequences, preferably not more than 10 nucleotides, and more preferably not more than 3 nucleotides. Within one embodiment of the invention, the *GAPI* promoter is provided free of coding sequence of the *P. methanolica GAPI* gene. However, those skilled in the art will recognize that a *GAPI* gene fragment that
35 includes the initiation ATG (nucleotides 1733 to 1735) of SEQ ID NO:1 can be operably linked to a heterologous coding sequence that lacks an ATG, with the *GAPI* ATG providing for initiation of translation of the heterologous sequence. Those skilled

in the art will further recognize that additional *GAP1* coding sequences can also be included, whereby a fusion protein comprising *GAP1* and heterologous amino acid sequences is produced. Such a fusion protein may comprise a cleavage site to facilitate separation of the *GAP1* and heterologous sequences subsequent to translation.

5 In addition to the *GAP1* promoter sequence, the present invention also provides transcription terminator sequences derived from the 3' non-coding region of the *P. methanolica* *GAP1* gene. A consensus transcription termination sequence (Chen and Moore, *Mol. Cell. Biol.* 12:3470-3481, 1992) is at nucleotides 2774 to 2787 of SEQ ID NO:1. Within the present invention, there are thus provided transcription
10 terminator gene segments of at least about 60 bp in length. Longer segments, for example at least 90 bp in length or about 200 bp in length, will often be used. These segments comprise the termination sequence disclosed above, and may have as their 5' termini nucleotide 2735 of SEQ ID NO:1. Those skilled in the art will recognize, however, that the transcription terminator segment that is provided in an expression
15 vector can include at its 5' terminus the TAA translation termination codon at nucleotides 2732-2734 of SEQ ID NO:1 to permit the insertion of coding sequences that lack a termination codon.

Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are well known in the art and are disclosed
20 by, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; Murray, ed., Gene Transfer and Expression Protocols, Humana Press, Clifton, NJ, 1991; Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994; Ausubel et al. (eds.), Short Protocols in
25 Molecular Biology, 3rd edition, John Wiley and Sons, Inc., NY, 1995; Wu et al., Methods in Gene Biotechnology, CRC Press, New York, 1997. DNA vectors, including expression vectors, commonly contain a selectable marker and origin of replication that function in a bacterial host (e.g., *E. coli*) to permit the replication and amplification of the vector in a prokaryotic host. If desired, these prokaryotic elements
30 can be removed from a vector before it is introduced into an alternative host. For example, such prokaryotic sequences can be removed by linearization of the vector prior to its introduction into a *P. methanolica* host cell.

Within one embodiment of the invention, expression vectors are provided that comprise a first DNA segment comprising at least a portion of the
35 sequence of SEQ ID NO:1 that is a functional transcription promoter operably linked to a second DNA segment encoding a protein of interest. When it is desired to secrete the protein of interest, the vector will further comprise a secretory signal sequence operably

linked to the first and second DNA segments. The secretory signal sequence may be that of the protein of interest, or may be derived from another secreted protein, preferably a secreted yeast protein. A preferred such yeast secretory signal sequence is the *S. cerevisiae* alpha-factor (*MF α 1*) pre-pro sequence (disclosed by Kurjan et al., U.S. Patent No. 4,546,082 and Brake, U.S. Patent No. 4,870,008).

Within other embodiments of the invention, expression vectors are provided that comprise a DNA segment comprising a portion of SEQ ID NO:1 that is a functional transcription terminator operably linked to an additional DNA segment encoding a protein of interest. Within one embodiment, the *P. methanolica* *GAP1* promoter and terminator sequences are used in combination, wherein both are operably linked to a DNA segment encoding a protein of interest within an expression vector.

Expression vectors of the present invention further comprise a selectable marker to permit identification and selection of *P. methanolica* cells containing the vector. Selectable markers provide for a growth advantage of cells containing them. The general principles of selection are well known in the art. The selectable marker is preferably a *P. methanolica* gene. Commonly used selectable markers are genes that encode enzymes required for the synthesis of amino acids or nucleotides. Cells having mutations in these genes cannot grow in media lacking the specific amino acid or nucleotide unless the mutation is complemented by the selectable marker. Use of such "selective" culture media ensures the stable maintenance of the heterologous DNA within the host cell. An exemplary selectable marker of this type for use in *P. methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21). See, Raymond, U.S. Patent No. 5,736,383. The *ADE2* gene, when transformed into an *ade2* host cell, allows the cell to grow in the absence of adenine. The coding strand of a representative *P. methanolica* *ADE2* gene sequence is shown in SEQ ID NO:2. The sequence illustrated includes 1006 nucleotides of 5' non-coding sequence and 442 nucleotides of 3' non-coding sequence, with the initiation ATG codon at nucleotides 1007-1009. Within one embodiment of the invention, a DNA segment comprising nucleotides 407-2851 is used as a selectable marker, although longer or shorter segments could be used as long as the coding portion is operably linked to promoter and terminator sequences. In the alternative, a dominant selectable marker, which provides a growth advantage to wild-type cells, may be used. Typical dominant selectable markers are genes that provide resistance to antibiotics, such as neomycin-type antibiotics (e.g., G418), hygromycin B, and bleomycin/phleomycin-type antibiotics (e.g., ZeocinTM; available from Invitrogen Corporation, San Diego, CA). An exemplary dominant selectable marker for use in *P. methanolica* is the *Sh bla* gene, which inhibits the activity of ZeocinTM.

The use of *P. methanolica* cells as a host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565; and U.S. Patents Nos. 5,716,808, 5,736,383, 5,854,039, and 5,888,768. Expression vectors for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. To facilitate integration of the expression vector DNA into the host chromosome, the entire expression segment of the plasmid can be flanked at both ends by host DNA sequences (e.g., *AUGI* 3' sequences). Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (τ) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

Integrative transformants are preferred for use in protein production processes. Such cells can be propagated without continuous selective pressure because DNA is rarely lost from the genome. Integration of DNA into the host chromosome can be confirmed by Southern blot analysis. Briefly, transformed and untransformed host DNA is digested with restriction endonucleases, separated by electrophoresis, blotted to a support membrane, and probed with appropriate host DNA segments. Differences in the patterns of fragments seen in untransformed and transformed cells are indicative of integrative transformation. Restriction enzymes and probes can be selected to identify transforming DNA segments (e.g., promoter, terminator, heterologous DNA, and selectable marker sequences) from among the genomic fragments.

Differences in expression levels of heterologous proteins can result from such factors as the site of integration and copy number of the expression cassette among individual isolates. It is therefore advantageous to screen a number of isolates for expression level prior to selecting a production strain. Isolates exhibiting a high expression level will commonly contain multiple integrated copies of the desired expression cassette. A variety of suitable screening methods are available. For example, transformant colonies are grown on plates that are overlaid with membranes (e.g., nitrocellulose) that bind protein. Proteins are released from the cells by secretion or following lysis, and bind to the membrane. Bound protein can then be assayed using known methods, including immunoassays. More accurate analysis of expression levels can be obtained by culturing cells in liquid media and analyzing conditioned media or cell lysates, as appropriate. Methods for concentrating and purifying proteins from

media and lysates will be determined in part by the protein of interest. Such methods are readily selected and practiced by the skilled practitioner.

For production of secreted proteins, host cells having functional deficiencies in the vacuolar proteases proteinase A, which is encoded by the *PEP4* gene, and proteinase B, which is encoded by the *PRB1* gene, can be used to minimize spurious proteolysis. Vacuolar protease activity (and therefore vacuolar protease deficiency) is measured using any of several known assays, such as those developed for *S. cerevisiae* and disclosed by Jones, *Methods Enzymol.* 194:428-453, 1991. One such assay is the APNE overlay assay, which detects activity of carboxypeptidase Y (CpY). See, Wolf and Fink, *J. Bact.* 123:1150-1156, 1975. Because the zymogen (pro)CpY is activated by proteinase A and proteinase B, the APNE assay is indicative of vacuolar protease activity in general. The APNE overlay assay detects the carboxypeptidase Y-mediated release of β -naphthol from N-acetyl-phenylalanine- β -naphthyl-ester (APNE), which results in the formation of an insoluble red dye by the reaction of the β -naphthol with the diazonium salt Fast Garnet GBC. Cells growing on assay plates (e.g., YEPD plates) at room temperature are overlaid with 8 ml RxM. RxM is prepared by combining 0.175 g agar, 17.5 ml H₂O, and 5 ml 1 M Tris-HCl pH 7.4, microwaving the mixture to dissolve the agar, cooling to ~55°C, adding 2.5 ml freshly made APNE (2 mg/ml in dimethylformamide) (Sigma Chemical Co., St. Louis, MO), and, immediately before assay, 20 mg Fast Garnet GBC salt (Sigma Chemical Co.). The overlay is allowed to solidify, and color development is observed. Wild-type colonies are red, whereas CPY deletion strains are white. Carboxypeptidase Y activity can also be detected by the well test, in which cells are distributed into wells of a microtiter test plate and incubated in the presence of N-benzoyl-L-tyrosine *p*-nitroanilide (BTPNA) and dimethylformamide. The cells are permeabilized by the dimethylformamide, and CpY in the cells cleaves the amide bond in the BTPNA to give the yellow product *p*-nitroaniline. Assays for CpY will detect any mutation that reduces protease activity so long as that activity ultimately results in the reduction of CpY activity.

P. methanolica cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A suitable culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories, Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine, 0.006% L-leucine).

For large-scale culture, one to two colonies of a *P. methanolica* strain can be picked from a fresh agar plate (e.g. YEPD agar) and suspended in 250 ml of

YEPD broth contained in a two-liter baffled shake flask. The culture is grown for 16 to 24 hours at 30°C and 250 rpm shaking speed. Approximately 50 to 80 milliliters of inoculum are used per liter starting fermentor volume (5 - 8% v/v inoculum).

A preferred fermentation medium is a soluble medium comprising
5 glucose as a carbon source, inorganic ammonia, potassium, phosphate, iron, and citric acid. As used herein, a "soluble medium" is a medium that does not contain visible precipitation. Preferably, the medium lacks phosphate glass (sodium hexametaphosphate). A preferred medium is prepared in deionized water and does not contain calcium sulfate. As a minimal medium, it is preferred that the medium lacks
10 polypeptides or peptides, such as yeast extracts. However, acid hydrolyzed casein (*e.g.*, casamino acids or amicas) can be added to the medium if desired. An illustrative fermentation medium is prepared by mixing the following compounds: $(\text{NH}_4)_2\text{SO}_4$ (11.5 grams/liter), K_2HPO_4 (2.60 grams/liter), KH_2PO_4 (9.50 grams/liter), $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (0.40 grams/liter), and citric acid (1.00 gram/liter). After adding distilled, deionized
15 water to one liter, the solution is sterilized by autoclaving, allowed to cool, and then supplemented with the following: 60% (w/v) glucose solution (47.5 milliliters/liter), 10x trace metals solution (20.0 milliliters/liter), 1 M MgSO_4 (20.0 milliliters/liter), and vitamin stock solution (2.00 milliliters/liter). The 10x trace metals solution contains $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (100 mM), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (2 mM), $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ (8 mM), $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ (8
20 mM), $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ (2 mM), $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ (1 mM), H_3BO_3 (8 mM), KI (0.5 mM), $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$ (1 mM), thiamine (0.50 grams/liter), and biotin (5.00 milligrams/liter). The vitamin stock solution contains inositol (47.00 grams/liter), pantothenic acid (23.00 grams/liter), pyridoxine (1.20 grams/liter), thiamine (5.00 grams/liter), and biotin (0.10 gram/liter). Those of skill in the art can vary these particular ingredients and amounts.
25 For example, ammonium sulfate can be substituted with ammonium chloride, or the amount of ammonium sulfate can be varied, for example, from about 11 to about 22 grams/liter.

After addition of trace metals and vitamins, the pH of the medium is typically adjusted to pH 4.5 by addition of 10% H_3PO_4 . Generally, about 10
30 milliliters/liter are added, and no additional acid addition will be required. During fermentation, the pH is maintained between about 3.5 to about 5.5, or about 4.0 to about 5.0, depending on protein produced, by addition of 5 N NH_4OH .

An illustrative fermentor is a BIOFLO 3000 fermentor system (New Brunswick Scientific Company, Inc.; Edison, NJ). This fermentor system can handle
35 either a six-liter or a fourteen-liter fermentor vessel. Fermentations performed with the six-liter vessel are prepared with three liters of medium, whereas fermentations performed with the fourteen-liter vessel are prepared with six liters of medium. The

fermentor vessel operating temperature is typically set to 30°C for the course of the fermentation, although the temperature can range between 27-31°C depending on the protein expressed. The fermentation is initiated in a batch mode. The glucose initially present is often used by approximately 10 hours elapsed fermentation time (EFT), at
5 which time a glucose feed can be initiated to increase the cell mass. An illustrative glucose feed contains 900 milliliters of 60% (w/v) glucose, 60 milliliters of 50% (w/v) (NH₄)₂SO₄, 60 milliliters of 10x trace metals solution, and 30 milliliters of 1 M MgSO₄. *P. methanolica* fermentation is robust and requires high agitation, aeration, and oxygen sparging to maintain the percentage dissolved oxygen saturation above 30%. The
10 percentage dissolved oxygen should not drop below 15% for optimal expression and growth. The biomass typically reaches about 30 to about 80 grams dry cell weight per liter at 48 hours EFT.

Proteins produced according to the present invention are recovered from the host cells using conventional methods. If the protein is produced intracellularly, the
15 cells are harvested (e.g., by centrifugation) and lysed to release the cytoplasmic contents. Methods of lysis include enzymatic and mechanical disruption. The crude extract is then fractionated according to known methods, the specifics of which will be determined for the particular protein of interest. Secreted proteins are recovered from the conditioned culture medium using standard methods, also selected for the particular
20 protein. See, in general, Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York, 1994.

The materials and methods of the present invention can be used to produce proteins of research, industrial, or pharmaceutical interest. Such proteins include enzymes, such as lipases, cellulases, and proteases; enzyme inhibitors,
25 including protease inhibitors; growth factors such as platelet derived growth factor (PDGF), fibroblast growth factors (FGF), epidermal growth factor (EGF), vascular endothelial growth factors (VEGFs); glutamic acid decarboxylase (GAD); cytokines, such as erythropoietin, thrombopoietin, colony stimulating factors, interleukins, and interleukin antagonists; hormones, such as insulin, proinsulin, leptin, and glucagon; and
30 receptors, including growth factor receptors, which can be expressed in truncated form ("soluble receptors") or as fusion proteins with, for example, immunoglobulin constant region sequences. DNAs encoding these and other proteins are known in the art. See, for example, U.S. Patents Nos. 4,889,919; 5,219,759; 4,868,119; 4,968,607; 4,599,311; 4,784,950; 5,792,850; 5,827,734; 4,703,008; 4,431,740; and 4,762,791; and WIPO
35 Publications WO 95/21920 and WO 96/22308.

The materials and methods of the present invention can be used to produce unglycosylated pharmaceutical proteins. Yeast cells, including *P. methanolica*

cells, produce glycoproteins with carbohydrate chains that differ from their mammalian counterparts. Mammalian glycoproteins produced in yeast cells may therefore be regarded as "foreign" when introduced into a mammal, and may exhibit, for example, different pharmacokinetics than their naturally glycosylated counterparts.

5 The invention is further illustrated by the following, non-limiting examples.

EXAMPLES

Example 1

10 To clone the *P. methanolica* GAP1 gene, sense (ZC11,356; SEQ ID NO:3) and antisense (ZC11,357; SEQ ID NO:4) PCR primers were designed from an alignment of the coding regions of GAPDH genes of *Saccharomyces cerevisiae*, *Kluyveromyces lactis*, and mouse. The primers were then used to amplify *P. methanolica* genomic DNA. An amplified sequence 608 bp long was recovered and
15 was found to have 78.1% homology to the corresponding *S. cerevisiae* GAPDH gene sequence.

 A *P. methanolica* genomic library was constructed in the vector pRS426 (Christianson et al., *Gene* 110:119-122, 1992), a shuttle vector comprising 2 μ and *S. cerevisiae* *URA3* sequences, allowing it to be propagated in *S. cerevisiae*. Genomic
20 DNA was prepared from strain CBS6515 according to standard procedures. Briefly, cells were cultured overnight in rich media, spheroplasted with zymolyase, and lysed with SDS. DNA was precipitated from the lysate with ethanol and extracted with a phenol/chloroform mixture, then precipitated with ammonium acetate and ethanol. Gel electrophoresis of the DNA preparation showed the presence of intact, high molecular
25 weight DNA and appreciable quantities of RNA. The DNA was partially digested with Sau 3A by incubating the DNA in the presence of a dilution series of the enzyme. Samples of the digests were analyzed by electrophoresis to determine the size distribution of fragments. DNA migrating between 4 and 12 kb was cut from the gel and extracted from the gel slice. The size-fractionated DNA was then ligated to
30 pRS426 that had been digested with Bam HI and treated with alkaline phosphatase. Aliquots of the reaction mixture were electroporated into *E. coli* MC1061 cells using an electroporator (Gene Pulser™; BioRad Laboratories, Hercules, CA) as recommended by the manufacturer.

 The library was screened by PCR using sense (ZC11,733; SEQ ID
35 NO:5) and antisense (ZC11,734; SEQ ID NO:6) primers designed from the sequenced region of the *P. methanolica* GAPDH gene fragment. The PCR reaction mixture was incubated for one minute at 94°C; followed by 34 cycles of 94°C, one minute, 52°C, 45

seconds, 72°C, two minutes; and a termination cycle of 94°C, one minute, 54°C, one minute, 72°C, eleven minutes. Starting with 43 library pools, positive pools were identified and broken down to individual colonies. A single colony with a pRS426 plasmid containing the *P. methanolica* GAPDH gene as its insert was isolated. The
5 orientation of the GAPDH gene and the length of the 5' and 3' flanking sequences in the insert were deduced by DNA sequencing (SEQ ID NO:1). This gene was designated *GAPI*.

A plasmid containing the *GAPI* gene, designated pGAPDH, has been deposited as an *E. coli* strain MC1061 transformant with American Type Culture
10 Collection, Manassas, VA under the terms of the Budapest Treaty. The deposited strain has been assigned the designation PTA-3 and a deposit date of May 4, 1999.

Example 2

The cloned *P. methanolica* *GAPI* promoter was used to construct an
15 expression cassette by replacing the *AUG1* promoter in the vector pCZR133 (disclosed in U.S. Patent No. 5,736,383). Plasmid pCZR133 comprises the *P. methanolica* *AUG1* promoter and terminator flanking a multiple cloning site, and a *P. methanolica* *ADE2* selectable marker. The *GAPI* promoter (nucleotides 810 to 1724 of SEQ ID NO:1) was amplified by PCR using primers that introduced a Not I site at the 5' end (SEQ ID
20 NO:7; ZC12,586), and Eco RI and Bam HI sites at the 3' end (SEQ ID NO:8; ZC12,565). The reaction mixture was incubated for one minute at 94°C; followed by 34 cycles of 94°C, one minute, 52°C, one minute, 72°C, three minutes; and a termination cycle of 94°C, one minute, 54°C, seven minutes, 72°C, 23 minutes. The amplified promoter was then blunt-end ligated into a phagemid vector (pBluescript®;
25 Stratagene, La Jolla, CA). The orientation of the promoter in the vector was determined by restriction analysis. The promoter was isolated as a Not I - Bam HI fragment. Plasmid pCZR133 was digested with Not I and Bam HI, and the digest was electrophoresed on a gel. Two fragments, the Ade2/termination fragment and the pUC fragment, were recovered. The pUC fragment was dephosphorylated. The two vector
30 fragments and the promoter were joined in a three-part ligation. The resulting plasmid was designated pBM/GAP (Fig. 1).

A second vector, pTAP76 (Fig. 2) was constructed. This vector comprises the *GAPI* promoter, α -factor prepro sequence, a SmaI cleavage site, the *AUG1* terminator, the *ADE2* selectable marker, and *AUG1* 3' non-coding sequence
35 cloned into a pRS316 (Sikorski and Hieter, *Genetics* 122:19-27, 1989) backbone. The pTAP76 vector is linearized at the SmaI site and combined with a DNA fragment of interest and double-stranded recombination linkers in *S. cerevisiae*, whereby the

fragment of interest is joined to the vector by homologous recombination as disclosed by Raymond et al., *BioTechniques* 26:134-141, 1999.

Example 3

5 Expression of heterologous genes from the *GAP1* promoter was tested using LacZ and GFP (green fluorescent protein) reporter genes. These genes were prepared as Eco RI-Bam HI fragments, and were individually ligated to Eco RI, Bam HI-digested pBM/GAP. The resulting plasmids were transformed into *P. methanolica* host cells, and the cells were grown in both glucose and methanol fermentation
10 conditions. Both reporter genes were expressed under both conditions, showing that the cloned *GAP1* promoter can be used to constitutively express heterologous genes in *P. methanolica* cells.

Example 4

15 To generate a *P. methanolica* strain deficient for vacuolar proteases, the *PEP4* and *PRB1* genes were identified and disrupted. *PEP4* and *PRB1* sequences were amplified by PCR in reaction mixtures containing 100 pmol of primer DNA, 1X buffer as supplied (Boehringer Mannheim, Indianapolis, IN), 250 μ M dNTPs, 1-100 pmol of template DNA, and 1 unit of Taq polymerase in a reaction volume of 100 μ l. The DNA
20 was amplified over 30 cycles of 94°C, 30 seconds; 50°C, 60 seconds; and 72°C, 60 seconds.

 Using an alignment of *PEP4* sequences derived from *S. cerevisiae* (Ammerer et al., *Mol. Cell. Biol.* 6:2490-2499, 1986; Woolford et al., *Mol. Cell. Biol.* 6:2500-2510, 1986) and *P. pastoris* (Gleeson et al., U.S. Patent No. 5,324,660), several
25 sense and antisense primers corresponding to conserved regions were designed. One primer set, ZC9118 (SEQ ID NO:9) and ZC9464 (SEQ ID NO:10) produced a PCR product of the expected size from genomic DNA, and this set was used to identify a genomic clone corresponding to the amplified region. DNA sequencing of a portion of this genomic clone (shown in SEQ ID NO:11) revealed an open reading frame encoding
30 a polypeptide (SEQ ID NO:12) with 70% amino acid identity with proteinase A from *S. cerevisiae*.

 Primers for the identification of *P. methanolica PRB1* were designed on the basis of alignments between the *PRB1* genes of *S. cerevisiae* (Moehle et al., *Mol. Cell. Biol.* 7:4390-4399, 1987), *P. pastoris* (Gleeson et al., U.S. Pat. No. 5,324,660),
35 and *Kluyveromyces lactis* (Fleer et al., WIPO Publication WO 94/00579). One primer set, ZC9126 (SEQ ID NO:13) and ZC9741 (SEQ ID NO:14) amplified a ca. 400 bp fragment from genomic DNA (SEQ ID NO:15). This product was sequenced and found

to encode a polypeptide (SEQ ID NO:16) with 70% amino acid identity with proteinase B from *S. cerevisiae*. The PRB primer set was then used to identify a genomic clone encompassing the *P. methanolica PRB1* gene.

Deletion mutations in the *P. methanolica PEP4* and *PRB1* genes were generated using available restriction enzyme sites. The cloned genes were restriction mapped. The *pep4Δ* allele was created by deleting a region of approximately 500 bp between BamHI and NcoI sites and including nucleotides 1 through 393 the sequence shown in SEQ ID NO:11. The *prb1Δ* allele was generated by deleting a region of approximately 1 kbp between NcoI and EcoRV sites and including the sequence shown in SEQ ID NO:15. The cloned *PEP4* and *PRB1* genes were subcloned into pCZR139, a phagemid vector (pBluescript® II KS(+), Stratagene, La Jolla, CA) that carried a 2.4 kb SpeI *ADE2* insert, to create the deletions. In the case of *PEP4* gene, the unique BamHI site in pCZR139 was eliminated by digestion, fill-in, and religation. The vector was then linearized by digestion with EcoRI and HindIII, and a ca. 4 kb EcoRI - HindIII fragment spanning the *PEP4* gene was ligated to the linearized vector to produce plasmid pCZR142. A ca. 500-bp deletion was then produced by digesting pCZR142 with BamHI and NcoI, filling in the ends, and religating the DNA to produce plasmid pCZR143. The *PRB1* gene (~5 kb XhoI - BamHI fragment) was subcloned into pCZR139, and an internal EcoRV - NcoI fragment, comprising the sequence shown in SEQ ID NO:15, was deleted to produce plasmid pCZR153.

Plasmid pCZR143 was linearized with Asp718, which cut at a unique site. The linearized plasmid was introduced into the *P. methanolica* PMAD11 strain (an *ade2* mutant generated as disclosed in U.S. Patent No. 5,736,383). Transformants were grown on ADE DS (Table 1) to identify Ade⁺ transformants. Two classes of white, Ade⁺ transformants were analyzed. One class arose immediately on the primary transformation plate; the second became evident as rapidly growing white papillae on the edges of unstable, pink transformant colonies.

Table 1

30	<u>ADE DS</u>
	0.056% -Ade -Trp -Thr powder
	0.67% yeast nitrogen base without amino acids
	2% D-glucose
	0.5% 200X tryptophan, threonine solution
35	18.22% D-sorbitol
	<u>-Ade -Trp -Thr powder</u>

powder made by combining 3.0 g arginine, 5.0 g aspartic acid, 2.0 g histidine, 6.0 g isoleucine, 8.0 g leucine, 4.0 g lysine, 2.0 g methionine, 6.0 g phenylalanine, 5.0 g serine, 5.0 g tyrosine, 4.0 g uracil, and 6.0 g valine (all L-amino acids)

200X tryptophan, threonine solution

3.0% L-threonine, 0.8% L-tryptophan in H₂O

For plates, add 1.8% Bacto™ agar (Difco Laboratories)

10 Southern blotting was used to identify transformants that had undergone the desired homologous integration event. 100 µl of cell paste was scraped from a 24-48 hour YEPD plate and washed in 1 ml water. Washed cells were resuspended in 400 µl of spheroplast buffer (1.2 M sorbitol, 10 mM Na citrate pH 7.5, 10 mM EDTA, 10 mM DTT, 1 mg/ml zymolyase 100T) and incubated at 37°C for 10 minutes. Four
15 hundred µl of 1% SDS was added, the cell suspension was mixed at room temperature until clear, 300 µl of 5 M potassium acetate was mixed in, and the mixture was clarified by microcentrifugation for 5 minutes. 750 µl of the clarified lysate was extracted with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1), 600 µl was transferred to a fresh tube, 2 volumes of 100% ethanol was added, and the DNA was
20 precipitated by microcentrifugation for 15 minutes at 4°C. The pellet was resuspended in 50 µl of TE (10 mM Tris pH 8.0, 1 mM EDTA) containing 100 µg/ml of RNAase A. Ten µl of DNA (approximately 100 ng) was digested in 100 µl total volume with appropriate enzymes, precipitated with 200 µl ethanol, and resuspended in 10 µl of DNA loading dye. The DNA was separated in 0.7% agarose gels and transferred to
25 nylon membranes (Nytran N⁺, Amersham Corp., Arlington Heights, IL) in a semi-dry blotting apparatus (BioRad Laboratories, Richmond, CA) as recommended by the manufacturer. Transferred DNA was denatured, neutralized, and cross-linked to the membrane with UV light using a Stratalinker (Stratagene, La Jolla, CA). To identify strains with a tandem integration at *PEP4*, two probes were used. One was a 1400 bp
30 EcoRI - HindIII fragment from the 3' end of *PEP4*. The second was a 2000 bp BamHI - EcoRI fragment from the 5' end of *PEP4*. Fragments were detected using chemiluminescence reagents (ECL™ direct labelling kit; Amersham Corp., Arlington Heights, IL).

35 Parent strains harboring a tandem duplication of the wild-type and deletion alleles of the gene were grown in YEPD broth overnight to allow for the generation of looped-out, Ade⁻ strains. These cells were then plated at a density of 2000-5000 colonies per plate on adenine-limited YEPD plates, grown for 3 days at

30°C and 3 days at room temperature. The shift to room temperature enhanced pigmentation of rare, pink, Ade⁻ colonies. Loop-out strains were consistently detected at a frequency of approximately one pink, Ade⁻ colony per 10,000 colonies screened. These strains were screened for retention of the wild-type or mutant genes by Southern blotting or by PCR using primers that spanned the site of the deletion. An *ade2-11 pep4Δ* strain was designated PMAD15.

The *PRB1* gene was then deleted from PMAD15 essentially as described above by transformation with plasmid pCZR153. Blots were probed with PCR-generated probes for internal portions of the *PRB1* and *ADE2* genes. The *PRB1* probe was generated by subcloning a 2.6 kb ClaI - SpeI fragment of *PRB1* into the phagemid vector pBluescript® II KS(+) to produce pCZR150, and amplifying the desired region by PCR using primers ZC447 (SEQ ID NO:17) and ZC976 (SEQ ID NO:18). The *ADE2* probe was generated by amplifying the *ADE2* gene in pCZR139 with primers ZC9079 (SEQ ID NO:19) and ZC9080 (SEQ ID NO:20). The resulting *ade2-11 pep4Δ prb1Δ* strain was designated PMAD16.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims

What is claimed is:

1. An isolated DNA molecule of up to 1500 nucleotides in length comprising nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.
2. A DNA construct comprising the following operably linked elements:
 - a first DNA segment comprising at least a portion of the sequence of SEQ ID NO:1 from nucleotide 733 to nucleotide 1732, wherein said portion is a functional transcription promoter;
 - a second DNA segment encoding a protein of interest other than a *Pichia methanolica* glyceraldehyde-3-phosphate dehydrogenase; and
 - a third DNA segment comprising a transcription terminator.
3. The DNA construct of claim 2 wherein said first DNA segment is from 900 to 1500 nucleotides in length.
4. The DNA construct of claim 2 wherein the first DNA segment comprises nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.
5. The DNA construct of claim 2 wherein the first DNA segment is essentially free of DNA encoding a *Pichia methanolica* glyceraldehyde-3-phosphate dehydrogenase.
6. The DNA construct of claim 2, further comprising a selectable marker.
7. The DNA construct of claim 2, further comprising a secretory signal sequence operably linked to the first and second DNA segments.
8. The DNA construct of claim 7, wherein the secretory signal sequence is a *Saccharomyces cerevisiae* alpha-factor pre-pro sequence.
9. The DNA construct of claim 2 wherein said third DNA segment comprises a transcription terminator of a *Pichia methanolica* *AUG1* or *GAP1* gene.
10. The DNA construct of claim 9, wherein said terminator comprises nucleotides 2735 to 2795 of SEQ ID NO:1.

11. A *Pichia methanolica* cell containing the DNA construct of claim 2.
12. The *Pichia methanolica* cell of claim 11 wherein the DNA construct is genomically integrated.
13. The *Pichia methanolica* cell of claim 12 wherein the DNA construct is genomically integrated in multiple copies.
14. The *Pichia methanolica* cell of claim 11 wherein the first DNA segment is from 900 to 1500 nucleotides in length.
15. The *Pichia methanolica* cell of claim 11 wherein the first DNA segment comprises nucleotide 810 to nucleotide 1724 of SEQ ID NO:1.
16. The *Pichia methanolica* cell of claim 11, wherein the cell is functionally deficient in vacuolar proteases proteinase A and proteinase B.
17. A method of producing a protein of interest comprising:
culturing the cell of claim 11 whereby the second DNA segment is expressed and the protein of interest is produced; and
recovering the protein of interest.
18. The method of claim 17 wherein the DNA construct is genomically integrated in multiple copies.
19. The method of claim 17, wherein the cell is deficient in vacuolar proteases proteinase A and proteinase B.
20. A DNA construct comprising the following operably linked elements:
a first DNA segment comprising a *Pichia methanolica* gene transcription promoter;
a second DNA segment encoding a protein of interest other than a *Pichia methanolica* protein; and
a third DNA segment comprising nucleotides 2735 to 2795 of SEQ ID NO:1.

1/2




Fig. 1

2/2




Fig. 2

SEQUENCE LISTING

<110> ZymoGenetics, Inc.
 Raymond, Christopher K.
 Vanaja, Erica
 Miller, Brady G.
 Sloan, James S.

<120> PICHIA METHANOLICA GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE 1
 PROMOTER AND TERMINATOR

<130> 98-56PC

<150> US 60/140,703

<151> 1999-06-24

<160> 20

<170> FastSEQ for Windows Version 3.0

<210> 1
 <211> 4409
 <212> DNA
 <213> Pichia methanolica

<220>
 <221> CDS
 <222> (1733)...(2734)

<400> 1

cccgggggat	cttattttct	gcaagaactt	aaccgagga	catgtcaaac	caagcatact	60
gtaaaagaaa	tagccgatgg	tttatatata	tatatacttg	cgttagtaga	aacagtttat	120
gcatgcatgg	atgcaagaac	tcagatatca	ggttatcaag	aaacatggag	aaattcctaa	180
acagaaacgg	aattaatccg	aaattctcgg	tctcccaaag	aaaatagatg	cacaagctaa	240
tacagcttgc	taactagctt	caactttcaa	aaaaaattct	aagctattga	atattcatca	300
agataatagt	ctatataaag	atgtaaagtc	attattattg	ggatatataa	acgtcctata	360
tattgctgaa	atgttaggtg	tatgtactga	aaacaatcag	tttgagttaa	ccagagagag	420
acgatggatc	tacagatcaa	tagagagaga	ataagatgag	aataagatga	ttaatagtga	480
gaggtagtag	ccactggcgg	gaggatgaaa	atatcccgga	taaacttaga	aagaaattaa	540
ttacacgtat	aggtaacatt	tgttattgtc	gaatctcaga	tcagttgatg	cctggaacag	600
atcgacttat	agatattatc	agatcataat	catgaggcga	ggtgcgacta	gtaccagggtg	660
atgatatatt	gtttccggtt	atttcaaata	gttgacgtcg	ttgtgtgatt	gggaaggcgt	720
cggagtaaca	gaaacagtaa	cggtacaagc	atcattatga	gttgagggta	tgtagggaag	780

cagttgtttg taagcatgtt tacaaatgca atgcatgtta cgattggact acaattaaat 840
 ccgaatgtac ctatataacg tgttgtacgt gttgtgccgt aagtagcccg atactagatg 900
 cttactacgt cactgatctg ttcggatctc agtccattca tgtgtcaaaa tagttagtag 960
 ctaaggggga tacaggggaag atgtttggta cgattatcgg agggatgtgt cttctgaggg 1020
 gggaggagag agggcgtgta aggagtttgt ttgtttgttt gtttgttgag agaagggggg 1080
 gagaagaggg ggtggtgggc tgatggcaat tgatatagag ggagagtgtg cgtaactgt 1140
 ttagtgtggt ggcggtacgg ggtacactgt agagggggac attataatgg ttatgtgtat 1200
 atgctgtata tatgaataca agtagggagt gactacacat tgcaattgat aatatgtgta 1260
 tgtgtgcgca tcagtatata cactcggagg ttctgaaagc catcattgta ttggacgttt 1320
 gaatggtatt agatgacttg ttgtactaga ggacggagaa tgggtgagtg gaagcaatag 1380
 ataataatgg aaagtttgct cgggtgtgga cattggcccg gagtagtgat accgtcacct 1440
 taaaattgca gttaggggat gatgctccgg ggcacgacct gccaaactaat ttaatagtcg 1500
 tctaacgctg gaacaggtgt tgttcacaaa gtagatgagt ttgttggttg gctggtcaaa 1560
 tgctgccttg atccatcgtt ttatatataa agactcactt ctccctcctct tgttcaattg 1620
 tttcacactc aactgcttct cccttatctt ttttttttcc ctgttttatt cccattgaa 1680
 ctagatcaca tcttttcata ttacacactt ttatttatta taattacaca aa atg gct 1738
 Met Ala
 1

att aac gtt ggt att aac ggt ttc ggt aga atc ggt aga tta gtc ttg 1786
 Ile Asn Val Gly Ile Asn Gly Phe Gly Arg Ile Gly Arg Leu Val Leu
 5 10 15

aga gtt gct tta tca aga aag gac atc aac att gtt gct gtc aat gat 1834
 Arg Val Ala Leu Ser Arg Lys Asp Ile Asn Ile Val Ala Val Asn Asp
 20 25 30

cct ttc att gct gct gaa tac gct gct tac atg ttc aag tac gat tcc 1882
 Pro Phe Ile Ala Ala Glu Tyr Ala Ala Tyr Met Phe Lys Tyr Asp Ser
 35 40 45 50

act cac ggt aag tac gcc ggc gaa gtt tcc agt gac ggt aaa tac tta 1930
 Thr His Gly Lys Tyr Ala Gly Glu Val Ser Ser Asp Gly Lys Tyr Leu
 55 60 65

atc att gat ggt aag aag att gaa gtt ttc caa gaa aga gac cca gtt 1978
 Ile Ile Asp Gly Lys Lys Ile Glu Val Phe Gln Glu Arg Asp Pro Val
 70 75 80

aac atc cca tgg ggt aaa gaa ggt gtc caa tac gtt att gac tcc act 2026
 Asn Ile Pro Trp Gly Lys Glu Gly Val Gln Tyr Val Ile Asp Ser Thr
 85 90 95

ggt gtt ttc act acc ttg gct ggt gct caa aag cac att gat gcc ggt Gly Val Phe Thr Thr Leu Ala Gly Ala Gln Lys His Ile Asp Ala Gly 100 105 110	2074
gct gaa aag gtt atc atc act gct cca tct gct gat gct cca atg ttc Ala Glu Lys Val Ile Ile Thr Ala Pro Ser Ala Asp Ala Pro Met Phe 115 120 125 130	2122
gtt gtt ggt gtt aac gaa aag gaa tac act tct gac ttg aag att gtt Val Val Gly Val Asn Glu Lys Glu Tyr Thr Ser Asp Leu Lys Ile Val 135 140 145	2170
tct aac gct tca tgt acc acc aac tgt ttg gct cca tta gct aag gtt Ser Asn Ala Ser Cys Thr Thr Asn Cys Leu Ala Pro Leu Ala Lys Val 150 155 160	2218
gtt aac gac aac ttt ggt att gaa tca ggt tta atg acc act gtc cac Val Asn Asp Asn Phe Gly Ile Glu Ser Gly Leu Met Thr Thr Val His 165 170 175	2266
tcc att acc gct acc caa aag acc gtc gat ggt cca tca cac aag gac Ser Ile Thr Ala Thr Gln Lys Thr Val Asp Gly Pro Ser His Lys Asp 180 185 190	2314
tgg aga ggt ggt aga act gct tcc ggt aac att atc cca tca tct act Trp Arg Gly Gly Arg Thr Ala Ser Gly Asn Ile Ile Pro Ser Ser Thr 195 200 205 210	2362
ggt gct gct aag gct gtt ggt aag gtt tta cct gtc tta gct ggt aag Gly Ala Ala Lys Ala Val Gly Lys Val Leu Pro Val Leu Ala Gly Lys 215 220 225	2410
tta acc ggt atg tct tta aga gtt cct act acc gat gtt tcc gtt gtt Leu Thr Gly Met Ser Leu Arg Val Pro Thr Thr Asp Val Ser Val Val 230 235 240	2458
gat tta acc gtt aac tta aag act cca acc act tac gaa gct att tgt Asp Leu Thr Val Asn Leu Lys Thr Pro Thr Thr Tyr Glu Ala Ile Cys 245 250 255	2506
gct gct atg aag aag gct tct gaa ggt gaa tta aag ggt gtt tta ggt Ala Ala Met Lys Lys Ala Ser Glu Gly Glu Leu Lys Gly Val Leu Gly 260 265 270	2554

gttgcttgct gctgattatg ctgttggtgg tttgttggtt gctgtttcgc agtcagttgg 4364
 aaatgatcca ctagtcttag agcggccgcc accgcggtgg agctc 4409

<210> 2

<211> 3077

<212> DNA

<213> *Pichia methanolica*

<400> 2

cagctgctct	gctccttgat	tcgtaattaa	tggtatcctt	ttactttgaa	ctcttgctcg	60
tccccaacag	ggattccaat	cggtgctcag	cgggatttcc	catgagggtt	ttgacaactt	120
tattgatgct	gcaaaaaact	tttagcccg	gtttaagtaa	ctgggcaata	tttccaaagg	180
ctgtgggcgt	tccacactcc	ttgcttttca	taatctctgt	gtattgtttt	attcgcat	240
tgattctctt	attaccagtt	atgtagaaag	atcggcaaac	aaaatatcaa	cttttatctt	300
gaacgctgac	ccacggtttc	aaataactat	cagaactcta	tagctatagg	ggaagtttac	360
tgcttgctta	aagcggctaa	aaagtgtttg	gcaaaattaa	aaagctgtga	caagtaggaa	420
ctcctgtaaa	gggccgattc	gacttcgaaa	gagcctaaaa	acagtgacta	ttggtgacgg	480
aaaattgcta	aaggagtact	agggctgtag	taataaataa	tggaacagtg	gtacaacaat	540
aaaagaatga	cgctgtatgt	cgtagcctgc	acgagtagct	cagtggtaga	gcagcagatt	600
gcaaatctgt	tggtcaccgg	ttcgatccgg	tctcgggctt	ccttttttgc	tttttcgata	660
tttgccggta	ggaagcaagg	tctagttttc	gtcgtttcgc	atggtttacg	aaagtatcag	720
ccatgagtgt	ttccctctgg	ctacctaata	tatttattga	tcggtctctc	atgtgaatgt	780
ttctttccaa	gttcggcttt	cagctcgtaa	atgtgcaaga	aatatttgac	tccagcgacc	840
tttcagagtc	aaattaattt	tcgctaacaa	tttgtgtttt	tctggagaaa	cctaaagatt	900
taactgataa	gtcgaatcaa	catcttttaa	tccttttagt	aagatctctg	cagcggccag	960
tattaaccaa	tagcatattc	acaggcatca	catcggaaca	ttcagaatgg	actcgcaaac	1020
tgtcgggatt	ttagggtggt	gccaacttgg	tcgtatgac	gttgaagctg	cacacagatt	1080
gaatatcaaa	actgtgattc	tcgaaaatgg	agaccaggct	ccagcaaagc	aaatcaacgc	1140
tttagatgac	catattgacg	gctcattcaa	tgatccaaaa	gcaattgccg	aattggctgc	1200
caagtgtgat	gttttaaccg	ttgagattga	acatgttgac	actgatgcgt	tggttgaagt	1260
tcaaaaggca	actggcatca	aaatcttccc	atcaccagaa	actatttcat	tgatcaaaga	1320
taaatacttg	caaaaagagc	atttgattaa	gaatggcatt	gctgttgccg	aatctttag	1380
tggtgaaagt	agcgcagcat	ctttagaaga	agttggtgcc	aaatacggct	tcccatat	1440
gctaaaatct	agaacaatgg	cctatgacgg	aagaggtaat	ttgttgtca	aagacaagtc	1500
atatatacct	gaagctttga	aagttttaga	tgacaggccg	ttatacggcg	agaaatgggc	1560
tccatittca	aaggagttag	ctgttatggt	tgtgagatca	atcgatggcc	aagtttat	1620
ctacccaact	gttgaaacca	tccacaaaaa	caacatctgt	cacactgtct	ttgctccagc	1680
tagagttaac	gatactgtcc	aaaagaaggc	caaatttttg	gctgacaacg	ctgtcaaata	1740
tttcccaggt	gctggtatct	ttggtgttga	aatgttttta	ttacaaaatg	gtgacttatt	1800
agtcaacgaa	attgccccaa	gacctacaaa	ttctggtcac	tataccatcg	acgcttgtgt	1860
cacctcgcaa	tttgaagctc	atgttagggc	cattactggg	ctacccatgc	cgaagaactt	1920
cacttgtttg	tcgactccat	ctacccaagc	tattatgttg	aacgttttag	gtggcgatga	1980
gcaaaacggt	gagttcaaga	tgtgtaaaaag	agcactagaa	actcctcatg	cttctgttta	2040

cttatacggg	aagactacaa	gaccaggcag	aaaaatgggt	cacattaata	tagttttctca	2100
atcaatgact	gactgtgagc	gtagattaca	ttacatagaa	ggtagcacta	acagcatccc	2160
tctcgaagaa	cagtacacta	cagattccat	tccgggcact	tcaagcaagc	cattagtcgg	2220
tgtcatcatg	ggttccgatt	cggacctacc	agtcattgtct	ctaggttgta	atatattgaa	2280
gcaatttaac	gttccatttg	aagtcactat	cgtttccgct	catagaaccc	cacaaagaat	2340
ggccaagtat	gccattgatg	ctccaaagag	agggttgaag	tgcattcattg	ctgggtgctgg	2400
tggtgccgct	catttaccgg	gaatgggtgc	ggcgatgacg	ccgctgcctg	ttattgggtgt	2460
ccctgttaaa	ggctctactt	tggatgggtgt	tgattcacta	cactccatcg	ttcaaagcc	2520
aagaggtatt	cctgttgcta	ctgtggctat	taacaatgct	actaacgctg	ccttgctagc	2580
tatcacaatc	ttaggtgccg	gcgatccaaa	tacttgtctg	caatggaagt	ttatatgaac	2640
aatatggaaa	atgaagtgtt	gggcaaggct	gaaaaattgg	aaaatgggtg	atatgaagaa	2700
tacttgagta	catacaagaa	gtagaacctt	ttatatgtga	tatagtactt	actcaaagtc	2760
ttaattgttc	taactgttaa	tttctgcttt	gcatttctga	aaagttaaag	acaagaaatc	2820
ttgaaatttc	tagttgctcg	taagaggaaa	cttgcatcca	aataacatta	acaataaatg	2880
acaataatat	attatttcaa	cactgctata	tggtagtttt	ataggttttg	ttaggatttg	2940
agatattgct	agcgtttatc	attatcctta	attgttcac	gacgcaaata	gacgcatttc	3000
cacaaaaatt	ttccgaacct	gtttttcact	tctccagatc	ttggtttagt	atagcttttg	3060
acacctaata	cctgcag					3077

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC11,356

<400> 3

ttacatgttc aagtacgat

19

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC11,357

<400> 4

tgatttcac gtaagtgg

18

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC11.733

<400> 5

atcccatggg gtaaagaagg

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC11.734

<400> 6

ataccgggta acttaccagc

20

<210> 7

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC12.586

<400> 7

ggtgcggccg caatgcatgt tacgattgg

29

<210> 8

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC12.565

<400> 8

ctagataaaa gagaagaaga gccaaagact ccacaaaaca ttgca

45

<210> 9

<211> 17
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC9118

<400> 9
 acctcccagt aagcctt

17

<210> 10
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC9464

<221> misc_feature
 <222> (1)...(17)
 <223> n = A,T,C or G

<400> 10
 ttyggnaart tygaygg

17

<210> 11
 <211> 421
 <212> DNA
 <213> Pichia methanolica

<220>
 <221> CDS
 <222> (2)...(421)

<400> 11
 g gaa ggt aac gtt tct cag gat act tta gct tta ggt gat tta gtt att 49
 Glu Gly Asn Val Ser Gln Asp Thr Leu Ala Leu Gly Asp Leu Val Ile
 1 5 10 15

cca aaa caa gac ttt gcc gaa gct act tct gag cca ggt tta gca ttc 97
 Pro Lys Gln Asp Phe Ala Glu Ala Thr Ser Glu Pro Gly Leu Ala Phe
 20 25 30

gca	ttt	ggt	aaa	ttt	gat	ggt	att	tta	ggt	tta	gct	tac	gat	agc	att	145
Ala	Phe	Gly	Lys	Phe	Asp	Gly	Ile	Leu	Gly	Leu	Ala	Tyr	Asp	Ser	Ile	
		35					40					45				
tcg	gtc	aac	aag	att	gtt	cct	cct	att	tat	aat	gct	tta	aac	ttg	ggt	193
Ser	Val	Asn	Lys	Ile	Val	Pro	Pro	Ile	Tyr	Asn	Ala	Leu	Asn	Leu	Gly	
		50					55				60					
tta	tta	gat	gaa	cct	caa	ttt	gcc	ttc	tac	cta	ggt	gat	act	aac	acc	241
Leu	Leu	Asp	Glu	Pro	Gln	Phe	Ala	Phe	Tyr	Leu	Gly	Asp	Thr	Asn	Thr	
		65				70				75					80	
aat	gaa	gaa	gat	ggt	ggt	ctt	gcc	act	ttt	ggt	ggt	ggt	gat	gag	tcc	289
Asn	Glu	Glu	Asp	Gly	Gly	Leu	Ala	Thr	Phe	Gly	Gly	Val	Asp	Glu	Ser	
				85					90					95		
aag	tat	act	ggt	aaa	ggt	aca	tgg	tta	cca	gtc	aga	aga	aag	gct	tac	337
Lys	Tyr	Thr	Gly	Lys	Val	Thr	Trp	Leu	Pro	Val	Arg	Arg	Lys	Ala	Tyr	
			100					105					110			
tgg	gaa	ggt	tca	tta	gac	ggt	att	tca	tta	ggt	gat	gaa	tac	gcg	cca	385
Trp	Glu	Val	Ser	Leu	Asp	Gly	Ile	Ser	Leu	Gly	Asp	Glu	Tyr	Ala	Pro	
		115					120					125				
tta	gaa	ggc	cat	gga	gct	gcc	att	gat	aca	ggt	acc					421
Leu	Glu	Gly	His	Gly	Ala	Ala	Ile	Asp	Thr	Gly	Thr					
		130				135					140					

Leu Leu Asp Glu Pro Gln Phe Ala Phe Tyr Leu Gly Asp Thr Asn Thr
 65 70 75 80
 Asn Glu Glu Asp Gly Gly Leu Ala Thr Phe Gly Gly Val Asp Glu Ser
 85 90 95
 Lys Tyr Thr Gly Lys Val Thr Trp Leu Pro Val Arg Arg Lys Ala Tyr
 100 105 110
 Trp Glu Val Ser Leu Asp Gly Ile Ser Leu Gly Asp Glu Tyr Ala Pro
 115 120 125
 Leu Glu Gly His Gly Ala Ala Ile Asp Thr Gly Thr
 130 135 140

<210> 13
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC9126

<400> 13
 atgtcaacac atttacc

17

<210> 14
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC9741

<221> misc_feature
 <222> (1)...(17)
 <223> n = A.T.C or G

<400> 14
 cayggnacnc aytgygc

17

<210> 15
 <211> 368
 <212> DNA
 <213> Pichia methanolica

<220>

<221> CDS

<222> (1)...(366)

<221> misc_feature

<222> (1)...(368)

<223> n = A,T,C or G

<400> 15

ggg tcc gna cnc atg gtg ttt cta aga att gcc cac att gtt gcc gtc	48
Gly Ser Xaa Xaa Met Val Phe Leu Arg Ile Ala His Ile Val Ala Val	
1 5 10 15	

aaa gtt tta aga tct aac ggt tca ggt tct atg ccc gat gtt gtc aag	96
Lys Val Leu Arg Ser Asn Gly Ser Gly Ser Met Pro Asp Val Val Lys	
20 25 30	

ggt gtt gaa tat gct ccc aat gct cac ctt gcg gaa gcc aag gct aac	144
Gly Val Glu Tyr Ala Pro Asn Ala His Leu Ala Glu Ala Lys Ala Asn	
35 40 45	

aag agt ggt ttt aaa ggt tct acc gcg aac atg tca tta ggt ggt ggt	192
Lys Ser Gly Phe Lys Gly Ser Thr Ala Asn Met Ser Leu Gly Gly Gly	
50 55 60	

aaa tct cca gct tta gat atg tct gtt aac gct cct gtt aaa gca ggt	240
Lys Ser Pro Ala Leu Asp Met Ser Val Asn Ala Pro Val Lys Ala Gly	
65 70 75 80	

tta cac ttt gcc gtt acc gct ggt aac gat aac act gat gca tgt aac	288
Leu His Phe Ala Val Thr Ala Gly Asn Asp Asn Thr Asp Ala Cys Asn	
85 90 95	

tat tct cca gcc act act gaa aat act gtc act gtt gtt gct tcc act	336
Tyr Ser Pro Ala Thr Thr Glu Asn Thr Val Thr Val Val Ala Ser Thr	
100 105 110	

tta tct gat tcg aga gct gac atg tct aac tc	368
Leu Ser Asp Ser Arg Ala Asp Met Ser Asn	
115 120	

<210> 16

<211> 122

<212> PRT

<213> Pichia methanolica

<220>

<221> VARIANT

<222> (1)...(122)

<223> Xaa = Any Amino Acid

<400> 16

Gly	Ser	Xaa	Xaa	Met	Val	Phe	Leu	Arg	Ile	Ala	His	Ile	Val	Ala	Val
1				5				10					15		
Lys	Val	Leu	Arg	Ser	Asn	Gly	Ser	Gly	Ser	Met	Pro	Asp	Val	Val	Lys
			20					25					30		
Gly	Val	Glu	Tyr	Ala	Pro	Asn	Ala	His	Leu	Ala	Glu	Ala	Lys	Ala	Asn
		35				40						45			
Lys	Ser	Gly	Phe	Lys	Gly	Ser	Thr	Ala	Asn	Met	Ser	Leu	Gly	Gly	Gly
	50				55					60					
Lys	Ser	Pro	Ala	Leu	Asp	Met	Ser	Val	Asn	Ala	Pro	Val	Lys	Ala	Gly
65					70					75					80
Leu	His	Phe	Ala	Val	Thr	Ala	Gly	Asn	Asp	Asn	Thr	Asp	Ala	Cys	Asn
				85					90					95	
Tyr	Ser	Pro	Ala	Thr	Thr	Glu	Asn	Thr	Val	Thr	Val	Val	Ala	Ser	Thr
			100					105					110		
Leu	Ser	Asp	Ser	Arg	Ala	Asp	Met	Ser	Asn						
		115					120								

<210> 17

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC447

<400> 17

taacaatttc acacagg

17

<210> 18

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC976

<400> 18

cgttgtaaaa cgacggcc

18

<210> 19

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC9079

<400> 19

cagctgccta ggactagttt cctcttacga gcaactaga

39

<210> 20

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC9080

<400> 20

tgatcaccta ggactagtga caagtaggaa ctcttgta

38

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/16671

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/81 C12N9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 14347 A (ZYMOGENETICS INC) 25 March 1999 (1999-03-25) cited in the application	1-7, 9-20
Y	page 13, line 13 - line 36	8, 16
Y	WO 98 20035 A (UNIV AUTONOMA DE NUEVO LEON ;VIADER SALVADO JOSE MARIA (MX); BARRE) 14 May 1998 (1998-05-14) cited in the application abstract	8
X	WO 97 17450 A (ZYMOGENETICS INC) 15 May 1997 (1997-05-15)	1-7, 9-15, 17-20
Y	page 12, line 18 -page 13, line 12 page 30, line 7 page 36, line 11 - line 12	8, 16
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 October 2000

Date of mailing of the international search report

18/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/16671

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 374 913 A (PHILLIPS PETROLEUM CO) 27 June 1990 (1990-06-27) the whole document -----	
A	EP 0 438 200 A (CIGB) 24 July 1991 (1991-07-24) abstract -----	
A	WATERHAM H R ET AL: "Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, GB, ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 186, no. 1, 20 February 1997 (1997-02-20), pages 37-44, XP004054877 ISSN: 0378-1119 the whole document -----	
A	DATABASE GENBANK 'Online! GI=2995611, Acc.no. U95625, 28 March 1998 (1998-03-28) SOHN, J.-H. ET AL.: "Pichia angusta glyceraldehyde 3-phosphate dehydrogenase gene, complete cds." XP002149526 the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/16671

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9914347 A	25-03-1999	AU 9231898 A AU 9396498 A EP 1015577 A WO 9914320 A	05-04-1999 05-04-1999 05-07-2000 25-03-1999
WO 9820035 A	14-05-1998	EP 0952158 A	27-10-1999
WO 9717450 A	15-05-1997	US 5955349 A US 5716808 A AU 1158297 A AU 712650 B AU 7673796 A CA 2237039 A CA 2237120 A EP 0889966 A EP 0862640 A JP 2000500014 T JP 2000500015 T WO 9717451 A US 6001597 A US 5965389 A US 5888768 A	21-09-1999 10-02-1998 29-05-1997 11-11-1999 29-05-1997 15-05-1997 15-05-1997 13-01-1999 09-09-1998 11-01-2000 11-01-2000 15-05-1997 14-12-1999 12-10-1999 30-03-1999
EP 0374913 A	27-06-1990	CA 2000101 A DK 656289 A JP 2222685 A NO 894916 A	22-06-1990 23-06-1990 05-09-1990 25-06-1990
EP 0438200 A	24-07-1991	CU 22276 B CU 22278 B CU 22287 B CU 22288 B JP 5184352 A	06-09-1994 06-09-1994 06-09-1994 06-09-1994 27-07-1993